Best Practices for 18 F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists
Funmilayo I. Tade, Rebecca A. Sajdak, CNMT, RT(N), FSNMMI-TS, Mehdat Gabriel, Robert H. Wagner, and Bital Savir-Baruch

18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. 18F-fluciclovine PET/CT is performed significantly differently from 18F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the 18F-fluciclovine PET/CT protocol.